Implantable Cardioverter Defibrillators Market: Size & Trends Shows a Rapid Growth by 2025

Implantable Cardioverter Defibrillators (ICD)s are battery-powered devices placed under the skin for keeping a track of heart rate. It has been proved quite useful in preventing sudden death in patients suffering from sustained ventricular tachycardia or fibrillation. ICD holds a critical role in preventing cardiac arrest in high-risk patients who are more prone to life-threatening ventricular arrhythmias. In this process, ICD is connected through thin wires with the patient’s heart.

Request a Free Sample of our Implantable Cardioverter Defibrillators Market: https://www.omrglobal.com/request-sample/implantable-cardioverter-defibrillators-market

The device delivers an electric shock to restore a normal heartbeat in case of an abnormal heart rhythm, if patient’s heart is beating chaotically and much too fast. Though ICDs have demonstrated clear life-saving benefits; concerns about patient acceptance along with psychological adjustment to the ICD have been the focus of much research.

As per researchers, the Quality of Life (QoL) of ICD patients can be better than that of those taking anti-arrhythmic medications. Usually, ICDs are composed of an ICD generator and wires; the first component consists of a programmable software, computer chip or circuitry with RAM (memory), a capacitor and a battery. There are two type of ICDS namely, Transvenous (TV) patients are vulnerable to complications such as fractures, which can turn to inappropriate therapy and infections. Additionally, a device-related infection rate generally varies between 0.67% and 1.49% over a 3 to 12-month follow-up. Moreover, mechanical lead failures can arouse from hardware malfunction, which can further result in inappropriate shocks, over sensing, and inability to deliver appropriate therapy. Furthermore, long-term lead failure rates up to 20% have been reported with Transvenous defibrillators.

Subcutaneous ICD is alternative novel technology used to limit complications associated with transvenous implantable cardioverter-defibrillator. Traditionally, S-ICD was used in patients with difficult venous access. As a result, congenital heart disease patients with venous anomalies are considered good candidates for S-ICD. Additionally, patients who are expected to outlive the life expectancy of their TV leads and requiring device extractions later in life can be ideal for S-ICD. It may also be used in patients with channelopathies or those who undergo renal replacement therapies and require chronic venous access.

A full Report of Implantable Cardioverter Defibrillators Market is Available at: https://www.omrglobal.com/industry-reports/implantable-cardioverter-defibrillators-market

Global Implantable Cardioverter Defibrillator Market Segmentation
By Product

• Transvenous Implantable CardioverterDefibrillator (T-ICDS)
• Subcutaneous Implantable CardioverterDefibrillator (S-ICDS)
By End-Users
• Hospitals
• Diagnostic Centers
• Ambulatory Service
• Homecare

Regional Analysis

• North America
• United States
• Canada
• Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
• Asia-Pacific
• China
• India
• Japan
• Rest of Asia-Pacific
• Rest of the World

Company Profiles

• Abbott Laboratories, Inc.
• Biotronik SE & Co. KG
• Cintas Corp.
• Defibtech, LLC
• General Electric Co.
• Koninklijke Philips N.V.
• LivaNova PLC
• Medtronic PLC
• Nihon Kohden Corp.
• Stryker Corp.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/implantable-cardioverter-defibrillators-market

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.